121 related articles for article (PubMed ID: 37805050)
41. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men.
Irwin DE; Milsom I; Reilly K; Hunskaar S; Kopp Z; Herschorn S; Coyne KS; Kelleher CJ; Artibani W; Abrams P
J Sex Med; 2008 Dec; 5(12):2904-10. PubMed ID: 19090944
[TBL] [Abstract][Full Text] [Related]
42. Cardiovascular risk profile in individuals initiating treatment for overactive bladder - Challenges and learnings for comparative analysis using linked claims and electronic medical record databases.
Vonesh E; Gooch KL; Khangulov V; Schermer CR; Johnston KM; Szabo SM; Rumsfeld JS
PLoS One; 2018; 13(10):e0205640. PubMed ID: 30325968
[TBL] [Abstract][Full Text] [Related]
43. Intravesical botulinum-A toxin in children with refractory non-neurogenic overactive bladder.
Lambregts AP; Nieuwhof-Leppink AJ; Klijn AJ; Schroeder RPJ
J Pediatr Urol; 2022 Jun; 18(3):351.e1-351.e8. PubMed ID: 35283021
[TBL] [Abstract][Full Text] [Related]
44. Prevalence, Risk Factors, and Treatment for Overactive Bladder in a Racially Diverse Population.
Mckellar K; Bellin E; Schoenbaum E; Abraham N
Urology; 2019 Apr; 126():70-75. PubMed ID: 30597170
[TBL] [Abstract][Full Text] [Related]
45. Association between gestational diabetes mellitus and subsequent overactive bladder among premenopausal female twins.
Tettamanti G; Iliadou AN; Pedersen NL; Bellocco R; Altman D
BJOG; 2013 Sep; 120(10):1289-95. PubMed ID: 23647812
[TBL] [Abstract][Full Text] [Related]
46. How durable is the effect of mirabegron in successfully-treated overactive bladder patients? Analysis of a multicentre study.
Švabík K; Mašata J; Krhut J; Zachoval R; Hanuš T; Halaška M; Martan A
Ceska Gynekol; 2018; 83(3):164-168. PubMed ID: 30764614
[TBL] [Abstract][Full Text] [Related]
47. Increased prevalence of metabolic syndrome in female patients with overactive bladder: A population-based study.
Anis O; Cohen AD; Aharony S; Kitrey ND; Dotan I; Shenhar C; Comaneshter D; Beckenstein T; Yaron S
Neurourol Urodyn; 2024 Jun; ():. PubMed ID: 38837822
[TBL] [Abstract][Full Text] [Related]
48. Persistence of overactive bladder pharmacological treatment in women as reflected from large-scale real-world data of prescription claims: A retrospective cohort study.
Karin L; Igor M; Chen S; Yariv S; Grotz O; Jack B; Ofer Y; Shachar A
Neurourol Urodyn; 2023 Sep; 42(7):1491-1498. PubMed ID: 37395464
[TBL] [Abstract][Full Text] [Related]
49. Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder.
Kitta T; Chiba H; Kon M; Higuchi M; Kusakabe N; Ouchi M; Togo M; Abe-Takahashi Y; Tsukiyama M; Shinohara N
J Pediatr Urol; 2022 Oct; 18(5):563-569. PubMed ID: 35965225
[TBL] [Abstract][Full Text] [Related]
50. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder.
Chancellor MB; Migliaccio-Walle K; Bramley TJ; Chaudhari SL; Corbell C; Globe D
Clin Ther; 2013 Nov; 35(11):1744-51. PubMed ID: 24091072
[TBL] [Abstract][Full Text] [Related]
51. Retrospective Observational Study of Treatment Patterns and Efficacy of onabotulinumtoxinA Therapy in Patients with Refractory Overactive Bladder in Clinical Practice.
Ko KJ; Lee KS
Toxins (Basel); 2023 May; 15(5):. PubMed ID: 37235372
[TBL] [Abstract][Full Text] [Related]
52. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
53. Overactive bladder medication: Persistence, drug switching, and reinitiation.
Soda T; Tashiro Y; Koike S; Ikeuchi R; Okada T
Neurourol Urodyn; 2020 Nov; 39(8):2527-2534. PubMed ID: 32985716
[TBL] [Abstract][Full Text] [Related]
54. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials.
Sand PK; Rovner ES; Watanabe JH; Oefelein MG
Drugs Aging; 2011 Feb; 28(2):151-60. PubMed ID: 21275440
[TBL] [Abstract][Full Text] [Related]
55. Prevalence of overactive bladder and its related factors in Japanese patients with diabetes mellitus.
Ikeda M; Nozawa K
Endocr J; 2015; 62(9):847-54. PubMed ID: 26166691
[TBL] [Abstract][Full Text] [Related]
56. Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study.
Chancellor MB; Yehoshua A; Waweru C; Globe D; Cheng IN; Campbell KL; Joshi M; Pulicharam R
Int Urol Nephrol; 2016 Jul; 48(7):1029-36. PubMed ID: 27032397
[TBL] [Abstract][Full Text] [Related]
57. Management of Patients with Overactive Bladder in Brazil: A Retrospective Observational Study Using Data From the Brazilian Public Health System.
Lozano-Ortega G; Ng DB; Szabo SM; Deighton AM; Riveros B; Guttschow A; Gooch KL; Gomes CM
Adv Ther; 2020 May; 37(5):2344-2355. PubMed ID: 32297282
[TBL] [Abstract][Full Text] [Related]
58. Correlation between psychological stress levels and the severity of overactive bladder symptoms.
Lai H; Gardner V; Vetter J; Andriole GL
BMC Urol; 2015 Mar; 15():14. PubMed ID: 25887525
[TBL] [Abstract][Full Text] [Related]
59. Overactive bladder in diabetes mellitus patients: a questionnaire-based observational investigation.
Palleschi G; Pastore AL; Maggioni C; Fuschi A; Pacini L; Petrozza V; Carbone A
World J Urol; 2014 Aug; 32(4):1021-5. PubMed ID: 24100404
[TBL] [Abstract][Full Text] [Related]
60. Association between metabolic syndrome and overactive bladder: a case-control study.
Saratlija Novakovic Z; Tesija RA; Puljak L
Scand J Urol; 2017 Dec; 51(6):470-473. PubMed ID: 28748747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
